These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 8512810

  • 1. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
    Tazzari PL, Zhang S, Chen Q, Sforzini S, Bolognesi A, Stirpe F, Xie H, Moretta A, Ferrini S.
    Br J Cancer; 1993 Jun; 67(6):1248-53. PubMed ID: 8512810
    [Abstract] [Full Text] [Related]

  • 2. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
    Sforzini S, de Totero D, Gaggero A, Ippoliti R, Glennie MJ, Canevari S, Stein H, Ferrini S.
    Br J Haematol; 1998 Sep; 102(4):1061-8. PubMed ID: 9734659
    [Abstract] [Full Text] [Related]

  • 3. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation.
    Tazzari PL, Bolognesi A, De Totero D, Lemoli RM, Fortuna A, Conte R, Crumpton MJ, Stirpe F.
    Br J Haematol; 1994 Jan; 86(1):97-105. PubMed ID: 7912101
    [Abstract] [Full Text] [Related]

  • 4. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
    Sforzini S, Bolognesi A, Meazza R, Marciano S, Tazzari PL, Stein H, Stirpe F, Ferrini S.
    J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380
    [Abstract] [Full Text] [Related]

  • 5. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
    Flavell DJ, Flavell SU, Boehm DA, Emery L, Noss A, Ling NR, Richardson PR, Hardie D, Wright DH.
    Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A, Tazzari PL, Olivieri F, Polito L, Lemoli R, Terenzi A, Pasqualucci L, Falini B, Stirpe F.
    Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
    Tazzari PL, Bolognesi A, de Totero D, Falini B, Lemoli RM, Soria MR, Pileri S, Gobbi M, Stein H, Flenghi L.
    Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
    [Abstract] [Full Text] [Related]

  • 9. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE, Brown AN, Bremner JA, Foxwell BM, Stirpe F.
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [Abstract] [Full Text] [Related]

  • 10. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ, Boehm DA, Noss A, Warnes SL, Flavell SU.
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [Abstract] [Full Text] [Related]

  • 11. Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
    Flavell DJ, Cooper S, Morland B, Flavell SU.
    Br J Cancer; 1991 Aug; 64(2):274-80. PubMed ID: 1716453
    [Abstract] [Full Text] [Related]

  • 12. Selective killing of CD4+ and CD8+ cells with immunotoxins containing saporin.
    Barbieri L, Bolognesi A, Dinota A, Lappi DA, Soria M, Tazzari PL, Stirpe F.
    Scand J Immunol; 1989 Sep; 30(3):369-72. PubMed ID: 2571186
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
    Flavell DJ, Cooper S, Okayama K, Emery L, Flavell SU.
    Hematol Oncol; 1995 Sep; 13(4):185-200. PubMed ID: 7557895
    [Abstract] [Full Text] [Related]

  • 14. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
    Flavell DJ, Boehm DA, Okayama K, Kohler JA, Flavell SU.
    Int J Cancer; 1994 Aug 01; 58(3):407-14. PubMed ID: 7519586
    [Abstract] [Full Text] [Related]

  • 15. Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies.
    Sforzini S, Bolognesi A, Meazza R, Marciano S, Casalini P, Dürkop H, Tazzari PL, Stein H, Stirpe F, Ferrini S.
    Br J Haematol; 1995 Jul 01; 90(3):572-7. PubMed ID: 7646996
    [Abstract] [Full Text] [Related]

  • 16. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins.
    Bolognesi A, Tazzari PL, Olivieri F, Polito L, Falini B, Stirpe F.
    Int J Cancer; 1996 Nov 04; 68(3):349-55. PubMed ID: 8903477
    [Abstract] [Full Text] [Related]

  • 17. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis.
    Bergamaschi G, Perfetti V, Tonon L, Novella A, Lucotti C, Danova M, Glennie MJ, Merlini G, Cazzola M.
    Br J Haematol; 1996 Jun 04; 93(4):789-94. PubMed ID: 8703804
    [Abstract] [Full Text] [Related]

  • 18. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
    Glennie MJ, Brennand DM, Bryden F, McBride HM, Stirpe F, Worth AT, Stevenson GT.
    J Immunol; 1988 Nov 15; 141(10):3662-70. PubMed ID: 3141503
    [Abstract] [Full Text] [Related]

  • 19. B-B10 (anti-CD25)-saporin immunotoxin--a possible tool in graft-versus-host disease treatment.
    Tazzari PL, Bolognesi A, De Totero D, Pileri S, Conte R, Wijdenes J, Hervé P, Soria M, Stirpe F, Gobbi M.
    Transplantation; 1992 Aug 15; 54(2):351-6. PubMed ID: 1496546
    [Abstract] [Full Text] [Related]

  • 20. Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.
    French RR, Courtenay AE, Ingamells S, Stevenson GT, Glennie MJ.
    Cancer Res; 1991 May 01; 51(9):2353-61. PubMed ID: 2015599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.